2023-507059-32-00
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.
VarmX B.V., VarmX B.V.1 site in 1 country48 target enrollmentNovember 17, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- VarmX B.V., VarmX B.V.
- Enrollment
- 48
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Clinical trial information desk
Scientific
VarmX B.V.
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Standard-of-Care Chemotherapy in Patients with Locally Advanced or Metastatic Solid Tumors2022-502615-11-00Genentech Inc., Genentech Inc.35
Not yet recruiting
Phase 1
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22
Active, not recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45